Wednesday, November 9, 2011
Boehringer Ingelheim GmbH, of Ingelheim, Germany, said results from the SILEN-C3 Phase IIb study showed the potential for BI201335, its next-generation protease inhibitor, in combination with pegylated interferon and ribavirin, to shorten treatment duration to 12 weeks and to improve the likelihood of viral cure compared to the former traditional standard of care pegylated interferon and ribavirin.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.